|
|
Blood, 1 October 2004, Vol. 104, No. 7, pp. 2194-2200.
Prepublished online as a Blood First Edition Paper on June 15, 2004; DOI 10.1182/blood-2003-07-2430.
 Previous Article | Next Article 
Submitted July 18, 2003
Accepted May 21, 2004
Physicians' attitudes about quality of life issues in hematopoietic stem cell transplantation
Stephanie J Lee*, Steven Joffe, Haesook T Kim, Gerard Socie, Andrew L Gilman, John R Wingard, Mary M Horowitz, David Cella, and Karen L Syrjala
Adult Oncology, Pediatrics, Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA
Service de greffe de moelle, Hopital St. Louis, Paris, France
Pediatrics, Children's Mercy Hosptial, Kansas City, MO, USA
Medicine, University of Florida College of Medicine, Gainesville, FL, USA
International Bone Marrow Transplant Registry, Milwaukee, WI, USA
Psychiatry and Behavioral Science, Northwestern University, Evanston, IL, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA, USA
* Corresponding author; email: sjlee{at}partners.org.
Studies investigating quality of life (QOL) after hematopoietic stem cell transplantation demonstrate the spectrum of QOL outcomes awaiting survivors. Nevertheless, how transplant physicians interpret and apply QOL information to clinical practice is poorly understood. We conducted a cross-sectional survey of transplant physicians to address these issues. Responses were received from 180 physicians (24%) in 29 countries. Seventy-two percent reported that their patients are willing to accept a poor QOL for a small chance of cure. Only 28% said that QOL considerations "often" or "almost all the time" enter into patients' decisions about transplantation. This contrasted with physicians' reported attention to QOL in their discussions with patients. While 53% of physicians reported using QOL results to modify practice, 55% would be more likely to use these data if they were more understandable. To assure generalizability of the results, a validation sample was randomly selected and these 85 physicians (response rate 76%) confirmed the findings of the original survey. Given the extensive data regarding post-transplant QOL, resources should be devoted to exploring how patients and physicians use these data in clinical care, and in devising methods to ensure that QOL results are interpretable and relevant to both patients and physicians.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Pidala, C. Anasetti, and H. Jim
Quality of life after allogeneic hematopoietic cell transplantation
Blood,
July 2, 2009;
114(1):
7 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Gondek, P.-P. Sagnier, K. Gilchrist, and J. M. Woolley
Current Status of Patient-Reported Outcomes in Industry-Sponsored Oncology Clinical Trials and Product Labels
J. Clin. Oncol.,
November 10, 2007;
25(32):
5087 - 5093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Grinstein, Y. Du, S. Santourlidis, J. Christ, M. Uhrberg, and P. Wernet
Nucleolin Regulates Gene Expression in CD34-positive Hematopoietic Cells
J. Biol. Chem.,
April 27, 2007;
282(17):
12439 - 12449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Parsons, M.-C. Shih, K. N. DuHamel, J. Ostroff, D. K. Mayer, J. Austin, D. R. Martini, S. E. Williams, L. Mee, S. Sexson, et al.
Maternal Perspectives on Children's Health-Related Quality of Life During the First Year After Pediatric Hematopoietic Stem Cell Transplant
J. Pediatr. Psychol.,
November 1, 2006;
31(10):
1100 - 1115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
